<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098250</url>
  </required_header>
  <id_info>
    <org_study_id>19-003200</org_study_id>
    <nct_id>NCT04098250</nct_id>
  </id_info>
  <brief_title>Multidisciplinary Translational Approach to Investigate Mechanisms Predictors &amp; Prevention of Persistent PTH</brief_title>
  <official_title>A Multidisciplinary Translational Approach to Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Genomics Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arizona State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phoenix VA Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a United States Department of Defense funded Focused Program study that aims to&#xD;
      identify mechanisms and predictors for persistent of post-traumatic headache attributed to&#xD;
      mild traumatic brain injury, and identify methods of preventing post-traumatic headache&#xD;
      persistence.&#xD;
&#xD;
      The objective of the clinical trial component of the Focused Program is to determine whether&#xD;
      intervention with erenumab is an effective treatment for PTH attributed to mTBI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The human studies component of this Focused Program includes clinical phenotyping,&#xD;
      neurophysiology, molecular and genetic biomarker discovery, brain imaging, and a clinical&#xD;
      trial.These data will be utilized to characterize post-traumatic headache and build&#xD;
      univariate and multivariate predictive models for post-traumatic headache persistence and for&#xD;
      the response to post-traumatic headache treatment. These studies are described in more detail&#xD;
      within a separate clinicaltrials.gov record.&#xD;
&#xD;
      The clinical trial is a double-blind, randomized, placebo-controlled investigation of&#xD;
      erenumab for the treatment of post-traumatic headache. Participants will be randomized when&#xD;
      PTH has been present for 35-56 days. Follow-up questionnaires, headache diary data, pain&#xD;
      threshold results, and brain imaging data will be collected longitudinally during the&#xD;
      clinical trial to assess for changes over time and associations of such changes with&#xD;
      post-traumatic headache treatment outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization to erenumab or placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Moderate-to-severe headache day frequency</measure>
    <time_frame>9-12 weeks</time_frame>
    <description>Moderate-to-severe headache day frequency measured at weeks 9-12 after administration of first dose of erenumab 140mg or placebo vs. frequency of moderate-to-severe headache days during the 4-week baseline phase (BP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder rate</measure>
    <time_frame>9-12 weeks</time_frame>
    <description>Percentage of patients with at least a 50% reduction in headache days during weeks 9-12 after administration of first dose of erenumab 140 mg or placebo compared to baseline phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic headache</measure>
    <time_frame>9-12 weeks</time_frame>
    <description>Percentage of patients with chronic headache, defined as at least 15 headache days, during weeks 9-12 after administration of first dose of erenumab 140 mg or placebo compared to baseline phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Impact Test (HIT-6)</measure>
    <time_frame>9-12 weeks</time_frame>
    <description>Headache Impact Test (HIT-6) score at weeks 9-12 after administration of first dose of erenumab 140 mg or placebo compared to baseline phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment day frequency</measure>
    <time_frame>9-12 weeks</time_frame>
    <description>Acute treatment day frequency measured at weeks 9-12 after administration of first dose of erenumab 140mg or placebo compared to baseline phase. Acute treatment day is any day on which analgesic, triptan, or ergotamine containing medication is taken, or device neuromodulation [e.g. vagal or trigeminal nerve electrical stimulation or single pulse transcranial magnetic stimulation] is administered to relieve headache.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Post-Traumatic Headache</condition>
  <arm_group>
    <arm_group_label>Erenumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>140 mg erenumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erenumab</intervention_name>
    <description>a CGRP receptor monoclonal antibody</description>
    <arm_group_label>Erenumab</arm_group_label>
    <other_name>Aimovig</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of acute PTH attributed to mild traumatic injury to the head as&#xD;
             defined by the International Classification of Headache Disorders (ICHD-3).&#xD;
&#xD;
          -  PTH onset 7-28 days prior to the time of enrollment&#xD;
&#xD;
          -  Adults 18-70 years of age&#xD;
&#xD;
          -  Willing to be randomized to either of the two clinical trial treatment arms&#xD;
&#xD;
          -  Willing to maintain a headache diary&#xD;
&#xD;
          -  Willing and able to return for follow-up visits&#xD;
&#xD;
          -  5 or more moderate or severe headache days during the 4-week run-in phase&#xD;
&#xD;
          -  At least 80% compliant with diary keeping during the 4-week run-in phase (i.e.,&#xD;
             provides data on at least 80% of days)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Episodic tension-type headache, migraine, or other headaches with at least 4 headache&#xD;
             days/month on average over the 6 months prior to the mTBI resulting in PTH&#xD;
&#xD;
          -  Previous history of chronic headache (i.e., at least 15 headache days/month) including&#xD;
             PPTH, chronic migraine, medication overuse headache, new daily persistent headache,&#xD;
             hemicrania continua, chronic tension-type headache&#xD;
&#xD;
          -  Diminished decision-making capacity that in the investigator's opinion would interfere&#xD;
             with the person's ability to provide informed consent and complete study procedures&#xD;
&#xD;
          -  Current or prior use of preventive medications for migraine or other primary headache&#xD;
             disorder&#xD;
&#xD;
          -  Use of onabotulinumtoxinA in the head, neck or face region within 12 months of&#xD;
             screening&#xD;
&#xD;
          -  During the 6 months before screening, use of opioids or barbiturates on an average of&#xD;
             at least 4 days per month&#xD;
&#xD;
          -  Subjects who underwent an intervention or used a device (e.g., nerve blocks,&#xD;
             transcranial magnetic stimulation, vagal nerve stimulation, or electrical trigeminal&#xD;
             nerve stimulation) for headache&#xD;
&#xD;
          -  History of major psychiatric disorder such as schizophrenia and bipolar disorder&#xD;
&#xD;
          -  History or evidence of any unstable or clinically significant medical condition, that&#xD;
             in the opinion of the investigator, would pose a risk to subject safety or interfere&#xD;
             with the study evaluation, procedures, or completion&#xD;
&#xD;
          -  History of positive neuroimaging findings that indicate a moderate or severe TBI&#xD;
&#xD;
          -  Contraindications to magnetic resonance imaging, including, but not limited to (only&#xD;
             an exclusion for patients participating in the brain MRI portion of this research):&#xD;
&#xD;
               1. Metal implants&#xD;
&#xD;
               2. Aneurysm clips&#xD;
&#xD;
               3. Severe claustrophobia&#xD;
&#xD;
               4. Implanted electronic device&#xD;
&#xD;
               5. Insulin or infusion pump&#xD;
&#xD;
               6. Cochlear/otologic/ear implant&#xD;
&#xD;
               7. Non-removable prosthesis&#xD;
&#xD;
               8. Implanted shunts/catheters&#xD;
&#xD;
               9. Certain intrauterine devices&#xD;
&#xD;
              10. Tattooed makeup&#xD;
&#xD;
              11. Body piercings that cannot be removed&#xD;
&#xD;
              12. Metal fragments&#xD;
&#xD;
              13. Wire sutures or metal staples&#xD;
&#xD;
          -  Factors that reduce MR image quality and interpretability (only an exclusion for&#xD;
             patients participating in the brain MRI portion of this research):&#xD;
&#xD;
               1. Dental braces or other non-removable devices (e.g., retainers)&#xD;
&#xD;
               2. Prior brain surgery&#xD;
&#xD;
               3. Known brain MRI abnormality that in the investigator's opinion will significantly&#xD;
                  impact MRI data&#xD;
&#xD;
          -  Sensory disorders that in the investigator's opinion might affect perception of&#xD;
             cutaneous thermal stimuli (e.g., peripheral neuropathy) (only an exclusion for&#xD;
             patients participating in the neurophysiology studies)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  History of myocardial infarction, stroke, transient ischemic attack, unstable angina,&#xD;
             coronary artery bypass surgery, or other revascularization procedures within 12 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Not willing to use a reliable form of contraception (for women of childbearing&#xD;
             potential) through 16 weeks after the last dose of erenumab. Acceptable methods of&#xD;
             birth control include not having intercourse, hormonal birth control methods,&#xD;
             intrauterine devices, surgical contraceptive methods, or two barrier methods (each&#xD;
             partner must use a barrier method) with spermicide. A reliable form of contraception&#xD;
             must be started prior to or at the time of starting the run-in phase. Not being of&#xD;
             childbearing potential is defined as any woman who is post-menopausal by history,&#xD;
             defined as:&#xD;
&#xD;
               1. At least 55 years of age with cessation of menses for 12 or more months; OR&#xD;
&#xD;
               2. Younger than 55 years of age but no spontaneous menses for at least 2 years; OR&#xD;
&#xD;
               3. Younger than 55 years of age and spontaneous menses within the past 1 year, but&#xD;
                  currently amenorrheic (e.g., spontaneous or secondary to hysterectomy), AND with&#xD;
                  postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating&#xD;
                  hormone levels at least 40 IU/L) or postmenopausal estradiol level (less than 5&#xD;
                  ng/dL) or according to the definition of &quot;postmenopausal range&quot; for the&#xD;
                  laboratory involved; OR&#xD;
&#xD;
               4. Underwent bilateral oophorectomy; OR&#xD;
&#xD;
               5. Underwent hysterectomy; OR&#xD;
&#xD;
               6. Underwent bilateral salpingectomy.&#xD;
&#xD;
          -  Currently or within 90 days prior to screening: received treatment in another drug&#xD;
             study or an investigational device study&#xD;
&#xD;
          -  Has previously received any CGRP ligand or receptor targeted monoclonal antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Schwedt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teri Radam</last_name>
    <phone>480-342-3775</phone>
    <email>Radam.Teri@Mayo.Edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix VA Health Care System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Ross, PhD</last_name>
      <phone>602-277-5551</phone>
      <phone_ext>7982</phone_ext>
      <email>Katherine.Ross3@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teri Radam, CCRP</last_name>
      <phone>480-342-3775</phone>
      <email>Radam.Teri@Mayo.Edu</email>
    </contact>
    <investigator>
      <last_name>Todd Schwedt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teri Radam, CCRP</last_name>
      <phone>480-342-3775</phone>
      <email>Radam.Teri@Mayo.Edu</email>
    </contact>
    <investigator>
      <last_name>Todd Schwedt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Todd J. Schwedt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>headache</keyword>
  <keyword>post-traumatic headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Traumatic Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erenumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

